Seeking Alpha

Sarepta rallies as Piper upbeat on eteplirsen NDA

  • Sarepta Therapeutics (SRPT +4.9%) is on the move, and with today's gains the shares are up some 10% since Wednesday when disappointing dystrophin production data from Prosensa's (RNA) drisapersen boosted sentiment around eteplirsen.
  • Today's catalyst appears to be a note out of Piper which emphasizes eteplirsen's safety profile.
  • SRPT is now up more than 50% since the end of August.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs